Organ Failure, Multiple

9

Review clinical trials related to Organ Failure, Multiple. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

ICU Background Early Awareness for Critical deterioratiON

The study will compare ICU sub-units, those with additional support of a clinician awareness system, ICU Beacon, and those receiving the standard of care. The win-ratio composite outcome will be assessed by comparing patients by study group and stratified by APACHE score at admission.

Participants needed: 1,962
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: ETH ZurichUpdated: Jun 15, 2026Locations: 1
Eligibility criteria

admission to intensive care unit

age < 18 years [+2]

Status: Recruiting

Heterogeneity of Critical Illness: a Cohort Study

Rationale: There is large heterogeneity in disease states of critically ill patients at ICU admittance and there is also large heterogeneity in their disease severity during ICU stay. Still, some patients may show remarkable similarities in disease patterns. There is a lack of understanding of causal mechanisms that lead to divergent outcomes in critically ill patients, and at the same time different diseases may share common underlying, yet unidentified, causal pathways that could explain similarities between different diseases. Objective: To explore the association between patient characteristics and the severity of organ failure in critically ill patients admitted to the ICU Study design: Prospective cohort study Study population: Adult critically ill patients in the ICU Intervention (if applicable): not applicable Main study parameters/endpoints: Maximum severity of organ failure observed during ICU stay measured by the maximum SOFA score and quality of life at one year follow-up

Participants needed: 5,000
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: University Medical Center GroningenUpdated: May 26, 2026Locations: 1Duration: 1 Year
Eligibility criteria

Adults Definition: age ≥18 years. [+1]

Planned admission [+9]

Status: Not yet recruiting

Sivelestat Treatment for Postoperative Organ Protection in Type A Aortic Dissection

The goal of this multicenter, double-blind, randomized controlled trial is to learn if sivelestat sodium (Siv) can protect the organ function in patients suffered operation for acute type A aortic dissection. The main questions it aims to answer are: * Can the 3-day-treatment of Siv enlarge the Day-0-to-Day-5 drop in the organ-health score (SOFA score)? * Can this treatment significantly shrink the area under the SOFA curve from first dose to Day 5? * Can this treatment significantly improve the end of patients in 28 days (clinical outcomes)? Researchers will compare drug Siv to a placebo (a look-alike substance that contains no drug) to see if drug Siv works. Participants will: * Take drug Siv or the placebo through vein continuously for 72 hours * Receiving regular intensive care in ICU after the operation

Participants needed: 236
Trial details
Phase: Phase 4Age: 18-75Biological sex: AllType: InterventionalSponsor: Shanghai Zhongshan HospitalUpdated: Sep 5, 2025Locations: 6
Eligibility criteria

Age 18-75 years inclusive. [+2]

Life expectancy ≤ 48 hours. [+7]

Status: Recruiting

Impact of Fourier Transform Infrared Spectroscopy (FTIRS) in ICUs

This study will assess the impact of FTIRS typing on the spread of ESBL-E in intensive care units

Participants needed: 900
Trial details
Age: 18-100Biological sex: AllType: InterventionalSponsor: University Hospital, CaenUpdated: Jul 24, 2025Locations: 1
Eligibility criteria

Adult patients hospitalized in ICU [+1]

none

Status: Recruiting

Evaluation of the Efficiency of Intermittent Enteral Nutrition on Multi-organ Failure From Patients With Mechanical Ventilation in Intensive Care Unit

This study aims to evaluate the efficiency of intermittent enteral nutrition versus continuous enteral nutrition to prevent from organ failures for patients at the acute phase of sepsis shock with mechanical ventilation in ICU.

Participants needed: 174
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: University Hospital, RouenUpdated: Jun 29, 2025Locations: 1
Eligibility criteria

Patient admitted in ICU for less than 48h, with invasive mechanical ventilation... [+7]

Contraindication to enteral nutrition and/or nasogastric tube insertion: esophag... [+6]

Status: Recruiting

Rectal Indomethacin as Early Treatment for Acute Pancreatitis (INDOMAP Trial)

Acute pancreatitis (AP) is an inflammatory condition of the pancreas following the activated pancreatic enzymes induced by varied causes, with or without other organ(s) dysfunction. The production and release of inflammatory factors is generally considered as the key factor of pathogenesis. Non-steroidal anti-inflammatory drugs (NSAIDs) are the most commonly applied agents for inflammatory diseases. A series studies have proved that indomethacin can reduce the risk of post-endoscopic retrograde cholangiopancreatography (ERCP), but high-quality evidence is still lacking in the field of effectiveness of NSAIDs to treat, rather than prevent, other types of AP. Majority of animal experiments showed that NSAIDs had protective effects for organ functions, but the results of several preliminary clinical studies were inconsistent. Randomized controlled trials are eagerly awaited to elucidate its effects on AP.

Participants needed: 1,504
Trial details
Phase: Phase 4Age: 18-80Biological sex: AllType: InterventionalSponsor: Peking Union Medical College HospitalUpdated: Jun 15, 2025Locations: 17
Eligibility criteria

Abdominal pain characteristic of AP [+2]

Onset time >24 hours [+11]

Status: Not yet recruiting

Safety, Tolerability and Performance of the NucleoCapture Extracorporeal Therapeutic Apheresis Device in the Reduction of Circulating cfDNA/NETs in Subjects With Pancreatitis

This is a single-centre, randomised-controlled, open-label, feasibility study to assess the safety, tolerability and performance of the NucleoCapture extracorporeal apheresis device in the reduction of circulating cell-free DNA (cfDNA)/Neutrophil Extracellular Traps (NETs) in patients with severe acute pancreatitis.

Participants needed: 20
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Liverpool University Hospitals NHS Foundation TrustUpdated: Mar 20, 2025Locations: 1
Eligibility criteria

Adult patients aged 18 or over [+4]

The use of other non-routine extracorporeal treatments such as very high flux re... [+24]

Status: Recruiting

Electronic Archive of Internal Medicine for the Treatment of Severe Organ Failure and Liver Transplantation-MITIGO

ELECTRONIC ARCHIVE OF INTERNAL MEDICINE FOR THE TREATMENT OF SERIOUS ORGAN FAILURES AND LIVER TRANSPLANTATION

Participants needed: 10,000
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: IRCCS Azienda Ospedaliero-Universitaria di BolognaUpdated: Jan 17, 2025Locations: 1Duration: 10 Years
Eligibility criteria

Diagnosis of acute or chronic liver disease or LT [+2]

no one

Status: Recruiting

The Impact and Effect of Traditional Chinese Medicine Treatment on Organ Failure in Critically Ill Patients

Critically ill patients are at risk of or suffering from one or more key organs or organ system failure. This study will measure the effect of traditional Chinese medicine(TCM) interventions on critically ill patients admitted to the intensive care unit (ICU). The goal of this clinical trial is to learn if traditional Chinese medicine(TCM) is effective for prevention and treatment of organ failure in ICU patients. Patients in this group will receive intervention for 2 weeks. A multi-center non-randomized real word data study, will include 3 groups: intervention group (TCM)(n=70), control group and historical control group (admitted to the same ICU in the period of 01.2019 to 12.2023). Main outcomes include sequential organ failure assessment (SOFA) score, ICU length of stay, hospital length of stay, number of days of respirator uses and western medicine medication used study follow up will be 2 weeks.

Participants needed: 350
Trial details
Age: 20+Biological sex: AllType: InterventionalSponsor: China Medical University HospitalUpdated: Jun 11, 2024Locations: 1
Eligibility criteria

Age 20 and above [+2]

Patients' family members refuse TCM intervention